1. Home
  2. NEXN vs CBIO Comparison

NEXN vs CBIO Comparison

Compare NEXN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexxen International Ltd. American Depository Shares

NEXN

Nexxen International Ltd. American Depository Shares

HOLD

Current Price

$5.66

Market Cap

367.2M

Sector

Technology

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$9.35

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEXN
CBIO
Founded
2007
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
367.2M
389.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NEXN
CBIO
Price
$5.66
$9.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
$12.00
$27.17
AVG Volume (30 Days)
357.9K
167.9K
Earning Date
03-04-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
237.45
N/A
EPS
0.62
N/A
Revenue
$376,353,000.00
N/A
Revenue This Year
$5.43
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.00
N/A
Revenue Growth
7.80
N/A
52 Week Low
$5.72
$9.43
52 Week High
$12.60
$21.40

Technical Indicators

Market Signals
Indicator
NEXN
CBIO
Relative Strength Index (RSI) 34.27 31.51
Support Level $5.81 $9.43
Resistance Level $6.39 $14.71
Average True Range (ATR) 0.28 1.23
MACD -0.01 -0.32
Stochastic Oscillator 8.33 5.61

Price Performance

Historical Comparison
NEXN
CBIO

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: